Motif Neurotech secures FDA IDE to initiate depression implant study

Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.
STAT

Zap in a cap: How one neurotech startup is using a hat to treat depression

FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat ...

A Brain Implant for Depression Is About to Be Tested in Humans

While many brain-computer interface companies are focused on helping paralyzed people communicate, Motif Neurotech is ...
Rutland Herald

Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression

Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that the ...